Failure of Exogenously Administered Interferon-γ or Blockage of Endogenous Interleukin-4 with Specific Inhibitors to Augment the Incidence of Autoimmune Diabetes in Male NOD Mice

References

• Rossini A. A., Handler E. S., Mordes J. P., Greiner D. L. Human autoimmune diabetes mellitus: Lessons from BB rats and NOD mice - Caveat Emptor. Clin. Immunol. Immunopathol. 1995; 74: 2–9
   PubMedGoogle Scholar
• Rabinovitch A., Suarez W. L., Sorensen O., Bleackley R. C., Power R. F. IFN-γ gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J. Immunol. 1995; 154: 4874–4882
   PubMed Web of Science ®Google Scholar
• Fox C. J., Danska J. S. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in non-obese diabetic mice. J. Immunol. 1997; 158: 2414–2424
   PubMed Web of Science ®Google Scholar
• Rabinovitch A., Suarez-Pinzon W. L., Sorensen O. Interleukin 12 mRNA expression in islets correlates with beta-cell destruction in NOD mice. J. Autoimmun. 1996; 9: 645–651
   PubMed Web of Science ®Google Scholar
• Rothe H., Faust A., Schade U., Kleeman R., Bosse G., Hibino T., Martin S., Kolb H. CvcloDhosuhamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetologia 1994; 37: 1154–1158
   PubMed Web of Science ®Google Scholar
• Pennline K. J., Roque-Gaffney E., Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol. 1994; 71: 169–175
   PubMedGoogle Scholar
• Nicoletti F., Zaccone P., Di Marco R., Di Mauro M., Magro G., Grasso S., Mughini L., Meroni P. L., Garotta G. The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in NOD mouse. Endocrinology 1996; 137: 5567–5575
   PubMed Web of Science ®Google Scholar
• Rapoport M. A., Jaramillo D., Zipris D., Lazarus A. H., Serreze D., Leiter E. H., Cyopick P., Danska J. S., Delovitch T. L. Interleukin-4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in non-obese diabetic mice. J. Exp. Med. 1993; 178: 87–99
   PubMed Web of Science ®Google Scholar
• Mueller R., Krahl T., Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 1996; 184: 1093–1099
   PubMed Web of Science ®Google Scholar
• Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation?. Diabetes 1994; 43: 613–621
   PubMed Web of Science ®Google Scholar
• Mandrup-Poulsen T., Nerup J., Reimers J. I., Pociot F., Andersen H. U., Karlsen A., Bjerre U., Bergholdt R. Cytokines and the endocrine system. II. Roles in substrate metabolism, modulation of thyroidal and pancreatic endocrine cell functions and autoimmune endocrine diseases. Eur. J. Endocrinol. 1996; 134: 21–30
   PubMed Web of Science ®Google Scholar
• Van der Meide P. H., Dubbeld M., Vijverberg K., Kos T., Schellekens H. The purification and characterization of rat gamma interferon by the use of two monoclonal antibodies. J. General. Virol. 1986; 67: 1059–1071
   PubMed Web of Science ®Google Scholar
• Gray P. W., Goeddel D. V. Cloning and expression of murine interferon cDNA. Proc. Natl. Acad. Sci. USA 1983; 80: 5842–5846
   PubMed Web of Science ®Google Scholar
• Boissier M. C., Chiocchia G., Bessis N., Hajnal J., Garotta G., Nicoletti F., Fournier C. Biphasic effect of interferon-y in murine collagen-induced arthritis. Eur. J. Immunol. 1995; 25: 1184–1190
   PubMed Web of Science ®Google Scholar
• Kawakami Y., Kuzuka N., Watanabe T., Uchiyama Y., Yamashita K. Induction of experimental thyroiditis in mice by recombinant interferon y administration. Acta Endocrinol. (Copenh.) 1990; 122: 41–48
   PubMedGoogle Scholar
• Jacob C. H., van der Meide P. H., McDevitt H. O. In vivo treatment of (NZB x NZW)FI lupus-like nephritis with monoclonal antibody to γ interferon. J. Exp. Med. 1987; 166: 798–802
   PubMed Web of Science ®Google Scholar
• Prat M., Gribaudo C., Comoglio P., Cavallo G., Landolfo S. Monoclonal antibodies against murine y interferon. Proc. Natl. Acad. Sci. USA 1984; 81: 4515–4519
   PubMed Web of Science ®Google Scholar
• Tang H., Mignon-Godefroy K., Meroni P. L., Garotta G., Charreire J., Nicoletti F. The effects of a monoclonal antibody to interferon-γ on Experimental Autoimmune Thyroiditis (EAT): prevention of disease and decrease of EAT-specific T cells. Eur. J. Immunol. 1993; 23: 275–279
   PubMed Web of Science ®Google Scholar
• Jacobs M. J.M., Van Den A. E.M., van Hoeck P. L.E.M., van de Lent A. J.J., Loovan de Putte L. B.A., Vander Berg W. B. Role of IL-2 and IL-4 in exacerbations of murine antigen-induced arthritis. Immunology 1994; 83: 390–396
   PubMed Web of Science ®Google Scholar
• Joosten L. A.B., Lubberts E., Durez P., Helsen M. A., Jacobs M. A., Goldman M., Van den Berg W. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Arthritis and Rheum. 1997; 40: 249–260
   PubMed Web of Science ®Google Scholar
• Hesse M., Bayrak S., Mitchison A. Protective major histocompatibility complex genes and the role of interleukin-4 in collagen-induced arthritis. Eur. J. Immunol. 1996; 26: 3234–3237
   PubMed Web of Science ®Google Scholar
• Mosley B., Beckmann M. P., March C. J., Idzerda R. L., Gimpcl S. D., Van den Bos T., Friend D., Alpert A., Anderson D., Jackson J., et al. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane hound forms. Cell 1989; 59: 335–348
   PubMed Web of Science ®Google Scholar
• Fanslow W. C., Clifford K. N., Park L. S., Rubin A. S., Voice R. F., Beckmann M. P., Widmer M. B. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J. Immunol. 1991; 147: 535–540
   PubMed Web of Science ®Google Scholar
• Gessner A., Schroppel K., Enssle K. H., Lauffer L., Rollinghoff M. Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous Leishmaniasis. Infect. Immun. 1994; 62: 4112–4117
   PubMed Web of Science ®Google Scholar
• Bagenstose L. M., Salgame P., Monestier M. IL-12 down-regulates autoantibody production in mercury-induced autoimmunity. J. Immunol. 1998; 160: 1612–1617
   PubMed Web of Science ®Google Scholar
• Parish N. M., Hutchings P. R., O'Reilly L., Quartey-Papafio L., Healey D., Ozegbe P., Cooke A. Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models. Immunol. Rev. 1995; 144: 269–300
   PubMed Web of Science ®Google Scholar
• Kelin B., Brailly H. Cytokine-binding proteins: stimulating antagonists. Immunol. Today 1995; 16: 216–220
   PubMedGoogle Scholar
• Swain S. L. CD4 T cell development and cytokine polarization: an overview. J. Leukoc. Bid. 1995; 57: 795–798
   PubMed Web of Science ®Google Scholar
• Satoh J., Seino H., Abo T., Tanaka S.-I., Shintani S., Ohta S., Taniura K., Sawai T., Nobunaga T., Oteki T., Kumagai K., Toyota T. Recombinant human tumor necrosis factor-α suppresses autoimmune diabetes in non-obese diabetic mice. J. Clin. Invest. 1989; 84: 1345–1348
   PubMed Web of Science ®Google Scholar
• Jacob C. O., Aiso S., Schreiber R. D., McDevitt H. O. Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development. Int. Immunol. 1992; 4: 611–614
   PubMed Web of Science ®Google Scholar
• Campbell I. L., Oxbrow L., Harrison L. C. Reduction of insulitis following administration of IFN-γ and TNF-α in the NOD mouse. J. Autoimmun. 1991; 4: 249–262
   PubMed Web of Science ®Google Scholar
• Piccirillo C. A., Chang Y., Prud G. J. 'honime. TGF-β1 somatic gene therapy prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol. 1998; 161: 3950–3956
   PubMed Web of Science ®Google Scholar
• Rothe H., O'Hara R. M., Martin S., Kolb H. Suppression of cyclophosphamide induced diabetes development and and pancreatic Thl reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)2. Diabetologia 1996; 39: 119–122
   PubMedGoogle Scholar
• Trembleau S., Penna G., Gregori S., Gately M. C., Adorini L. Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur. J. Immunol. 1997; 27: 2330–2339
   PubMed Web of Science ®Google Scholar
• Doth M., Fricke M., Nicoletti F., Garotta G., Van-Velthuhysen M.-L., Brujin J. A., Gleichmann E. Genetic differences in immune reactivity to mercuric chloride (HgCl2): immunosuppression of H-2d mice is mediated by interferon-γ (TFN-γ). Clin. ESP. Immunol. 1997; 109: 149–156
   PubMed Web of Science ®Google Scholar
• Ochel M., Vohr H.-W., Pfeiffer C., Gleichman E. IL-4 required for the TgE and IgGl increase and IgGl autoantibody formation in mice treated with mercuric chloride. J. Immunol. 1991; 146: 3006–3011
   PubMed Web of Science ®Google Scholar
• Nicoletti F., Di Marco R., Barcellini W., Magro G., Schorlemmer H. U., Kurrle R., Lunetta M., Grasso S., Zaccone P., Meroni P. L. Protection from experimental autoimmune diabetes in the nonobese diabetic mouse with soluble interleukin-1 receptor. Eur. J. Immunol. 1994; 24: 1843–1847
   PubMed Web of Science ®Google Scholar
• Nicoletti F., Zaccone P., Di Marco R., Magro G., Grasso S., Stivala F., Calori G., Mughini L., Meroni P. L., Garotta G. Paradoxical antidiabetogenic effect of γ-interferon in DP-BB rats. Diabetes 1998; 47: 32–38
   PubMed Web of Science ®Google Scholar
• Valente G., Ozmen L., Novelli F., Geuna M., Palestro G., Forni G., Garotta G. Distribution of interferon-y receptor in human tissues. Eur. J. Immunol. 1992; 22: 2403–2412
   PubMed Web of Science ®Google Scholar
• Landolfo S., Garotta G. IFN-γ. An immunomodulatory and proinflammatory lymphokine. J. Immunol. Res. 1991; 9: 81–94
   Google Scholar
• Wang B., Gonzalez A., Hoglund P., Katz J. D., Benoist C., Mathis D. Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes 1998; 47: 1207–1211
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Cytokines and natural regulatur of cytokines. Immunol. Lett. 1994; 43: 111–123
   PubMed Web of Science ®Google Scholar
• McKenzie G. J., Bancroft A., Grencis R. K., McKenzie A. N. A distinct role for interleukin-13 in Th2 cell mediated immune responses. Curr. Biol. 1998; 8: 339–342
   PubMed Web of Science ®Google Scholar
• Yang X. D., Tisch R., Singer S. M., Cao Z. A., Liblau R. S., Schreiber R. D., McDevitt H. O. Effect of tumor necrosis factor-α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J. Exp. Med. 1994; 180: 995–1004
   PubMed Web of Science ®Google Scholar
• Amital H., Levi Y., Blank M., Barak V., Langevitz P., Afek A., Nicoletti F., Kopolovic J., Gilburd B., Meroni P. L., Shoenfeld Y. Immunomodulation of murine experimental SLE-like disease by interferon-γ. Lupus 1998; 7: 445–454
   PubMed Web of Science ®Google Scholar